The safety, clinical efficacy and prognostic factors of transcatheter arterial chemoembolization (TACE) and/or hepatic artery infusion chemotherapy (HAIC) combined with targeted immunotherapy for primary hepatocellular carcinoma (HCC) require further in-depth study. This research aims to evaluate the safety, clinical efficacy and prognostic factors of TACE and/or HAIC combined with targeted immunotherapy for hepatocellular carcinoma. We are going to compare and analyze local tumor response, survival outcomes, prognostic factors and adverse events. Tumor response was evaluated according to the modified Response Evaluation Criteria in Solid Tumors (mRECIST) version. Adverse events were evaluated using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. This study intends to include the targeted and immunotherapy applied, mainly including: lenvatinib, sorafenib, apatinib, bevacizumab, etc.; pembrolizumab, carfilzomib, sintilimab and teprotumumab, etc.
Study Type
OBSERVATIONAL
Enrollment
120
transarterial chemoembolization
Jiayan Ni
Guangzhou, None Selected, China
RECRUITINGOverall survival(OS)
OS was calculated as the duration from the date of the first cycle of the study combination therapy to the date of death or last date of follow-up.
Time frame: 1-, 2-, 3-, and 5-year
Progression-free survival (PFS)
PFS was defined as the duration from the date of the first cycle of the combination therapy to tumor lesion progression, death, or last follow-up, whichever came first.
Time frame: 1-, 2-, and 3-year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.